Atherosclerosis
Low cholesterol, mortality, and quality of life in old age during a 39-year follow-up

https://doi.org/10.1016/j.jacc.2004.04.057Get rights and content
Under an Elsevier user license
open archive

Objectives

We assessed the impact of serum cholesterol level in early midlife on total mortality during up to 39 years of follow-up and on the quality of life (QoL) in old age.

Background

Total effects of low serum cholesterol on health have been in dispute, especially in elderly persons, and there are few data on the long-term effects of low cholesterol on QoL.

Methods

The cohort consisted of 3,277 healthy businessmen age 30 to 45 years at baseline (1960s). In addition to baseline, serum cholesterol values were available for part of the cohort in 1974, 1986, and 2000. The QoL was assessed in 80.9% of survivors (n = 1,820, mean age 73 years) with a RAND-36 (SF-36) QoL questionnaire in 2000. Mortality up to 2002 (n = 1,173) was retrieved from national registers.

Results

Cholesterol was clearly reduced in survivors during follow-up, except in the lowest baseline serum cholesterol group. Baseline cholesterol predicted 39-year total mortality in a graded manner (p < 0.0001), and a value ≤5.0 mmol/l was associated with a 25% reduction in total mortality. In old age, the physical component summary score of RAND-36 was significantly (p = 0.02) higher (better) in the lowest baseline cholesterol group; no difference was found in the mental component summary score (p = 0.51).

Conclusions

Low serum cholesterol level in midlife predicted not only better survival but also better physical function and QoL in old age, without adversely affecting mental QoL.

Abbreviations and acronyms

MCS
mental component summary
PCS
physical component summary
QoL
quality of life
SF-36
Short Form-36

Cited by (0)

The Päivikki and Sakari Sohlberg Foundation, the Helsinki University Central Hospital, and the Finnish Foundation for Cardiovascular Research have provided financial support. Dr. Strandberg is a senior research fellow of the Academy of Finland (Grant 48613). All authors have cooperated with companies marketing cholesterol-lowering drugs.